A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases

This study compared the ADRs of Lecanemab and Aducanumab, revealing that ARIA was the most common AE for both drugs. However, Lecanemab showed a lower risk of ARIA, cerebral hemorrhage, and severe events. These findings emphasize the need for further clinical research to clarify the long-term safety and efficacy of both drugs.

Authors

Jun Yong He (ORCID: https://orcid.org/0000-0001-8056-0347)
Hongyu Ye (ORCID: https://orcid.org/0009-0008-0360-8974)
Yihan Zhang (ORCID: https://orcid.org/0000-0002-3546-9752)
Yunhan Zhao (ORCID: https://orcid.org/0000-0002-3002-8296)
Haoxiang Hu
Jiesheng Mao
Xiaokai Yang

Institutions

Wenzhou Medical University (CN)

Publication Details

Journal: Frontiers in Pharmacology
Published: 2025-04-01
DOI: https://doi.org/10.3389/fphar.2025.1561020
Citations: 3
Primary Topic: Pharmacovigilance and Adverse Drug Reactions
Type: article
Field-Weighted Citation Impact: 3.92

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases

Jun Yong He, Hongyu Ye, Yihan Zhang, Yunhan Zhao et al.

Apr 1, 2025

3 citations

Frontiers in Pharmacology

Pharmacovigilance and Adverse Drug Reactions

3.92

article

A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases

Jun Yong He, Hongyu Ye, Yihan Zhang, Yunhan Zhao, Haoxiang Hu, Jiesheng Mao, Xiaokai Yang

April 1, 2025article en

3 citations

Abstract

This study compared the ADRs of Lecanemab and Aducanumab, revealing that ARIA was the most common AE for both drugs. However, Lecanemab showed a lower risk of ARIA, cerebral hemorrhage, and severe events. These findings emphasize the need for further clinical research to clarify the long-term safety and efficacy of both drugs.

Frontiers in PharmacologyVol. 16

Wenzhou Medical University (CN)

Good health and well-being

Openalex Percentile: Top 8%

Pharmacovigilance and Adverse Drug Reactions

3.92

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases — Jun Yong He, Hongyu Ye, et al. · Frontiers in Pharmacology (2025) | TGRS Research Map | TGRS